Dr. Michael B. Williams, M.D.
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at San Antonio (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 1,348
Licensed in Texas since 2008, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2003Medical school: University of Texas Medical School at San Antonio
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
VA license 0101249728 · TX license N1955 (first issued 2008; delinquent - incomplete registration)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sentara Norfolk General Hospital Norfolk, VA
- Sentara Leigh Hospital Norfolk, VA
- Sentara Princess Anne Hospital Virginia Beach, VA
- Sentara Obici Hospital Suffolk, VA
- Chesapeake General Hospital Chesapeake, VA
Medical groups
- Urology of Virginia, PLLC (72 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,348
- Services billed
- 25,931
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Bcg live intravesical instillation, 1 mg | 13,950 | 87 |
| Injection, degarelix, 1 mg | 4,160 | 35 |
| Injection, denosumab, 1 mg | 2,340 | 20 |
| Automated urinalysis test | 980 | 483 |
| Established patient office or other outpatient visit, 30-39 minutes | 771 | 504 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 702 | 84 |
| Diagnostic exam of bladder and urethra using an endoscope | 389 | 243 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 333 | 68 |
| Instillation of anti-cancer drug into bladder | 332 | 99 |
| Psa (prostate specific antigen) measurement, total | 320 | 200 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Virginia Beach, VA | 299 |
| Finasteride Other prescribers in Virginia Beach, VA | 165 |
| Erleada (apalutamide) | 106 |
| Prednisone Other prescribers in Virginia Beach, VA | 99 |
| Abiraterone Acetate | 85 |
| Trospium Chloride Other prescribers in Virginia Beach, VA | 75 |
| Xtandi (enzalutamide) | 63 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Virginia Beach, VA | 57 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Virginia Beach, VA | 53 |
| Nubeqa (darolutamide) | 45 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 68 payments worth $32,684 in total to this clinician.
| Ferring Pharmaceuticals Inc. | $23,592 |
|---|---|
| Janssen Biotech, Inc. | $6,538 |
| Janssen Scientific Affairs, LLC | $1,555 |
| Janssen Global Services, LLC | $500 |
| Bayer HealthCare Pharmaceuticals Inc. | $138 |
| Immunitybio, Inc. | $88.45 |
| Pfizer Inc. | $63.71 |
| Merck Sharp & Dohme LLC | $44.66 |
| Compensation for services other than consulting (speaking, faculty) | $20,283 |
|---|---|
| Consulting Fee | $9,332 |
| Food and Beverage | $1,814 |
| Travel and Lodging | $1,180 |
| Education | $76.60 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ferring Pharmaceuticals Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $7,125 |
| Ferring Pharmaceuticals Inc. Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $4,043 |
| Janssen Biotech, Inc. May 9, 2025 | Consulting Fee | $4,024 |
| Ferring Pharmaceuticals Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $2,850 |
| Ferring Pharmaceuticals Inc. Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $1,900 |
| Ferring Pharmaceuticals Inc. Aug 13, 2025 | Consulting Fee ADSTILADRIN · ONCOLOGY | $1,900 |
| Ferring Pharmaceuticals Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $1,470 |
| Ferring Pharmaceuticals Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $1,470 |
| Ferring Pharmaceuticals Inc. Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $1,425 |
| Janssen Scientific Affairs, LLC Nov 24, 2025 | Consulting Fee ERLEADA · Oncology | $1,410 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 8, 2025 | Education ERLEADA · Oncology · in-kind | $68.00 |
| Janssen Scientific Affairs, LLC Nov 24, 2025 | Consulting Fee ERLEADA · Oncology | $1,410 |
| Ferring Pharmaceuticals Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $7,125 |
| Janssen Global Services, LLC Sep 8, 2025 | Consulting Fee | $500 |
| Ferring Pharmaceuticals Inc. Aug 13, 2025 | Consulting Fee ADSTILADRIN · ONCOLOGY | $1,900 |
| Janssen Biotech, Inc. Jul 25, 2025 | Consulting Fee | $272 |
| Janssen Biotech, Inc. Jul 8, 2025 | Consulting Fee | $681 |
| Janssen Biotech, Inc. Jun 18, 2025 | Consulting Fee | $545 |
| Janssen Biotech, Inc. May 9, 2025 | Consulting Fee | $4,024 |
| Ferring Pharmaceuticals Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $2,850 |
| Bayer HealthCare Pharmaceuticals Inc. May 7, 2025 | Education Nubeqa · Oncology · in-kind | $8.60 |
| Janssen Biotech, Inc. Apr 23, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $136 |
| Janssen Biotech, Inc. Apr 23, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $117 |
| Ferring Pharmaceuticals Inc. Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $1,900 |
| Ferring Pharmaceuticals Inc. Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $1,425 |
| Janssen Biotech, Inc. Apr 4, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $333 |
| Ferring Pharmaceuticals Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $1,470 |
| Ferring Pharmaceuticals Inc. Mar 20, 2025 | Travel and Lodging ADSTILADRIN · ONCOLOGY · travel to HUNTINGDON VALLEY, PA · in-kind | $188 |
| Ferring Pharmaceuticals Inc. Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $4,043 |
| Ferring Pharmaceuticals Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $1,470 |
| Ferring Pharmaceuticals Inc. Feb 20, 2025 | Travel and Lodging ADSTILADRIN · ONCOLOGY · travel to NORFOLK, VA · in-kind | $405 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $213,865 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06510374 - A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasiv…
Merck Sharp & Dohme LLC - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
Ferring Pharmaceuticals As · Terminated · NCT06026332 - Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Dendreon Pharmaceuticals LLC · Recruiting · NCT06134232 - A phase 3 multinational randomized openlabel three parallelarm study of PF06801591 an ANTIPD1 antibody in combination with bacillus calmetteguerin bcg induction with or without bcg maintenance versus bcg induction and…
Pfizer Inc. - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.